World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
81
Citations
28940
World Ranking
1542
National Ranking
771

Medicine

D-Index
82
Citations
29146
World Ranking
15967
National Ranking
8035

Overview

Christopher T. Ritchlin is affiliated with the University of Rochester Medical Center in the United States. Their research primarily focuses on the fields of Medicine and Immunology and Microbiology, with significant contributions to subfields such as Rheumatology, Immunology, Hematology, Oncology, and Dermatology.

The scientist's work covers several key topics, including:

  • Psoriasis: Treatment and Pathogenesis
  • Spondyloarthritis Studies and Treatments
  • Autoimmune and Inflammatory Disorders Research
  • Rheumatoid Arthritis Research and Therapies
  • Dermatology and Skin Diseases
  • Systemic Lupus Erythematosus Research
  • Lymphatic System and Diseases

Christopher T. Ritchlin has contributed to a wide range of scientific publications, frequently publishing in journals such as:

  • Annals of the Rheumatic Diseases
  • Arthritis & Rheumatology
  • Lara D. Veeken
  • The Journal of Rheumatology
  • Journal of the American Academy of Dermatology

Several recent papers demonstrate the scope of their research, including:

  • "Notch signalling drives synovial fibroblast identity and arthritis pathology," 2020, Nature
  • "Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial," 2020, The Lancet
  • "Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial," 2020, The Lancet
  • "Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)," 2022, The Lancet
  • "Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial," 2020, The Lancet

The scientist has collaborated frequently with several coauthors, including:

  • Iain B. McInnes
  • Philip J. Mease
  • Joseph F. Merola
  • Laura C. Coates
  • A. Kollmeier

Overall, Christopher T. Ritchlin's research portfolio reflects extensive involvement in autoimmune and inflammatory diseases, with a specific focus on psoriatic arthritis and related treatments, contributing substantially to the understanding and development of therapies in rheumatology and immunology.

Best Publications

  • Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double‐blind, randomized, placebo‐controlled trial

    Philip P.J. Mease;Dafna D.D. Gladman;Christopher C.T. Ritchlin;Eric E.M. Ruderman

  • Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis

    Laura C. Coates;Arthur Kavanaugh;Philip J. Mease;Enrique R. Soriano

  • Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2) : a randomised, double-blind, placebo-controlled, phase 3 trial

    Iain B McInnes;Philip J Mease;Bruce Kirkham;Arthur Kavanaugh

  • Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial

    Iain B McInnes;Arthur Kavanaugh;Alice B Gottlieb;Lluís Puig

  • Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial

    Christopher Ritchlin;Proton Rahman;Arthur Kavanaugh;Iain B McInnes

  • Mechanisms of TNF-α– and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis

    Christopher T. Ritchlin;Sally A. Haas-Smith;Ping Li;David G. Hicks

  • Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force

    Josef S Smolen;Monika Schöls;Jürgen Braun;Maxime Dougados

  • Treatment recommendations for psoriatic arthritis

    C. T. Ritchlin;A. Kavanaugh;D. D. Gladman;P. J. Mease

  • Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1

    Philip J Mease;Désirée van der Heijde;Christopher T Ritchlin;Masato Okada

  • 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis

    Jasvinder A. Singh;Gordon Guyatt;Alexis Ogdie;Dafna D. Gladman

  • Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force

    Josef S. Smolen;Jürgen Braun;Maxime Dougados;Paul Emery

  • European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies

    L Gossec;J S Smolen;C Gaujoux-Viala;Z Ash

  • Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.

    Jasvinder A. Singh;Gordon Guyatt;Alexis Ogdie;Dafna D. Gladman

  • Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis

    Philip J. Mease;Mark C. Genovese;Maria W. Greenwald;Christopher T. Ritchlin

  • Patterns of cytokine production in psoriatic synovium.

    C Ritchlin;S A Haas-Smith;D Hicks;J Cappuccio

  • Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial.

    Philip Mease;Mark C. Genovese;Geoffrey Gladstein;Alan J. Kivitz

  • Adalimumab for long‐term treatment of psoriatic arthritis: Forty‐eight week data from the adalimumab effectiveness in psoriatic arthritis trial

    Dafna D. Gladman;Philip J. Mease;Christopher T. Ritchlin;Ernest H. S. Choy

  • Constitutive production of inflammatory and mitogenic cytokines by rheumatoid synovial fibroblasts

    R Bucala;C Ritchlin;R Winchester;A Cerami

  • Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials

    Arthur Kavanaugh;Christopher Ritchlin;Proton Rahman;Lluis Puig

  • Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)

    P J Mease;P Ory;J T Sharp;C T Ritchlin

Frequent Co-Authors

Philip J. Mease
Philip J. Mease University of Washington
Edward M. Schwarz
Edward M. Schwarz University of Rochester Medical Center
Dafna D. Gladman
Dafna D. Gladman Toronto Western Hospital
Arthur Kavanaugh
Arthur Kavanaugh University of California, San Diego
Alice B. Gottlieb
Alice B. Gottlieb Icahn School of Medicine at Mount Sinai
Iain B. McInnes
Iain B. McInnes University of Glasgow
Oliver FitzGerald
Oliver FitzGerald University College Dublin
Philip S. Helliwell
Philip S. Helliwell University of Leeds
Wolf-Henning Boehncke
Wolf-Henning Boehncke University of Geneva
Robert Landewé
Robert Landewé University of Amsterdam

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Immunology in the USA opens doors to various related online degrees and career pathways, particularly in healthcare. Many Immunology graduates consider advancing their qualifications through specialized nursing programs to enhance their clinical expertise and job prospects.

For example, those currently working as Family Nurse Practitioners (FNPs) might explore the fnp to acute care np bridge program, which allows a smooth transition to acute care settings, expanding clinical responsibilities and potential earnings.

Many students also benefit from enrolling in an accelerated nurse practitioner program, designed to fast-track degree completion with flexible online formats.

For those without a nursing background, there are online accelerated nursing programs for non nurses that provide a direct pathway into nursing careers without traditional prerequisites.

Additionally, many institutions offer 12-month accelerated nursing programs, allowing students to earn a Bachelor of Science in Nursing quickly and enter the workforce sooner.

Overall, pairing immunology studies with these nursing pathways equips graduates to engage in diverse clinical roles, contributing significantly to patient care and research advancements.

Best Scientists Citing Christopher T. Ritchlin

Trending Scientists

Recently Published Articles